HOME >> BIOLOGY >> NEWS
Erodible plastic microspheres could be effective oral drug delivery system

given orally to the rats, the scientists found dicumarol first appeared in the bloodstream within two hours and persisted for three days. For insulin, blood sugar levels were reduced within two hours. The plasmid DNA was incorporated into cells of the liver and small intestine and produced an active protein within five days.

Moreover, use of the microspheres greatly enhanced the drugs' availability in the bloodstream. For example, the increase in activity of dicumarol could be explained by intestinal uptake of up to 47 percent of the microspheres after feeding. Usually, when dicumarol is administered orally, very little of it is absorbed. In the study, the dicumarol also remained in plasma for much longer periods than other forms of the drug orally dispensed to the animals, resulting in improved availability. Insulin and plasmid DNA cannot be administered orally because they are degraded by the harsh conditions of the intestinal tract.

Potential applications of this drug delivery system--to replace therapeutic agents not taken orally today--exist in gene therapy and in the use of vaccines; in treating AIDS, cancer and diabetes; and for delivering medication to inflamed intestines. Proteins, such as insulin, growth hormone, and erythropoetin (used to treat anemia) are examples of drugs that would benefit from this new form of oral delivery. The delivery of corrective gene sequences in the form of plasmid DNA could provide convenient therapy for a number of genetic diseases such as cystic fibrosis and hemophilia.

Edith Mathiowitz, who led the study, thinks the enhanced absorption relates in part to the small size of the spheres and the adhesive nature of the polymers. The spheres were engineered to stick tightly to and even penetrate linings in the gastrointestinal tract before transferring their contents over time into the circulation system.

"The study indicates uptake of entire micro
'"/>

Contact: Edith Mathiowitz
Edith_Mathiowitz@Brown.edu
401-863-1358
Brown University
27-Mar-1997


Page: 1 2 3

Related biology news :

1. Clemson University spin-off uses corn to make plastics, provide cleaner air
2. Hope available for patients with anemia and myelodysplastic syndrome
3. Consumer education and development of bio-sensitive alternatives can revive the plastics industry
4. Component in plastic bottles found to cause abnormal pregnancies in mice
5. Biodegradable plastics go to compost heaps, not landfills
6. NIST chemists define and refine properties of plastic microsystems
7. Efficient plastic nuggets key to agricultural plastic waste disposal
8. Dearborn, Mich., researchers receive award for improving automobile plastics
9. Monitoring epithelial plasticity, one cell at a time
10. T cell responses in aplastic anemia
11. Plants as plants: gene could convert crops to plastics factories

Post Your Comments:
(Date:11/21/2014)... NEW YORK , Nov. 19, 2014  Earlier ... Board at New York College, and one of the ... for biosensor signals that are transmitted from Smartphones to ... there were Smartphones and has one of the earliest ... are discussing its usage in the military, child care, ...
(Date:11/18/2014)... , Nov. 17, 2014   ... EMC collaborate to develop The Partners Data Lake, ... The Partners Data Lake will allow researcher and ... diagnostics, treatment and the lives of patients ... and clinical activities across the Partners system, breaking ...
(Date:11/11/2014)... -- Forensicon, Inc., a Chicago -based digital ... promotion of Yaniv Schiff from Senior Computer ... new role as Director, he will lead company efforts ... and provide leadership within the company,s digital forensics practice ... Schiff joined Forensicon in 2006 and ...
Breaking Biology News(10 mins):Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
Cached News: